The Hilton Hotel in Kuncheng was almost booked out by representatives of global pharmaceutical giants and large domestic pharmaceutical companies.
In the past few days, medical representatives have been in and out of hotels, and they meet countless colleagues every day.
Everyone was smiling when they met, but looking back, they were secretly inquiring about other colleagues' plans. At the same time, they judged each other's expressions to guess whether there had been any real progress in the negotiations with Sanqing Pharmaceutical.
People from Sanqing Pharmaceutical smile to people from pharmaceutical companies every day, making their mouths dry and their faces frozen with laughter.
But everyone was in high spirits, proud and full of energy.
Wei Kang has not been idle these days. He has discussed with Sun Chengren that if Sanqing Pharmaceutical wants to develop rapidly, in addition to funds, it also needs strong sales channels.
This channel includes not only the domestic market, but also the channels for drugs to be launched abroad.
The domestic channels are okay. Sanqing Pharmaceutical has been established for many years and has already established its own sales system. There is no problem in developing channels in the domestic market.
Moreover, this new anti-cancer drug has filled a gap in the field of domestic new drug research and development, and will definitely receive support from the state, and its future launch will be smooth.
But after all, Sanqing Pharmaceutical is a small pharmaceutical company with no foreign sales channels, and it is difficult to establish and improve it on its own in just a few years.
For the top big pharmaceutical companies, if they want to enter a country's market, there are many ways they can do it. Whether it is a sole proprietorship or a joint venture to build a factory, or cooperation with a local company, it is all simple and easy. .
Through these simple methods, they can quickly expand sales channels in a country without encountering too many obstacles.
For international pharmaceutical giants such as Pfizer, Bayer, and Johnson & Johnson, they not only have strong funds, but also have top-notch resources and connections in various countries, and their sales channels have been established long ago.
They can get a drug into hospitals, clinics, pharmacies and other medical institutions in dozens or even hundreds of countries in the shortest possible time and without any effort.
And they don’t need to spend too much on marketing and publicity. Their brand alone is a guarantee of efficacy, and they can gain the trust of patients and actively choose their drugs.
Not only do patients trust the efficacy of top pharmaceutical companies, but more importantly, if there is a problem, they can also get sky-high compensation from them.
Such reputation is even more important than the efficacy.
Just like Pfizer, it once received the largest fine in the history of a single company, breaking a world record and leaving giants in other industries far behind.
In 2009, Pfizer paid $2.3 billion to settle a lawsuit accused of improperly marketing a blockbuster drug, Bextra, and concealing potential adverse effects.
This is the fourth time Pfizer has been punished for the same reason, and nearly every global pharmaceutical company has been hit with this accusation.
Therefore, if people will continue to trust pharmaceutical giants such as Pfizer in the future, it will only be because of the increasingly higher fines.
After all, even the largest fine in the world is just three weeks of Pfizer's sales.
People want to believe that even if something goes wrong with big-brand medicines, they can receive high enough compensation.
This is an advantage that other companies cannot match.
Therefore, for Sanqing, cooperation is the fastest way to make money, and it can also continuously strengthen its own assets and enhance brand awareness in the shortest time.
But how to cooperate is something Wei Kang needs to weigh.
In the past few days, cooperation applications from all pharmaceutical companies have been submitted, and each pharmaceutical company has several quotation plans.
Co-development, buyout at a fixed price, and overall acquisition of all assets of Sanqing Pharmaceutical, including drug R&D laboratories.
These pharmaceutical companies still refused to give up and offered large buyout and acquisition prices in an attempt to impress Wei Kang.
Especially the prices offered by multinational giants are more ruthless than the others.
Wei Kang didn't expect that Bayer could actually offer a price of 10 billion euros.
When Sun Chengren saw the price on the plan, he couldn't help but shake his hands.
"Uncle Sun, is this price very tempting?"
"Ten billion, or Euros. If you sell it, you can retire directly and you won't have to worry about it in the next life."
Lao Sun stroked his chest, nodded and said: "It would be a lie to say that I am not interested. When I saw this number, my heart almost stopped. And the price can definitely be negotiated again. If Sanqing's major shareholder is me, I will I definitely agreed, since I’m almost 50 anyway, so it wouldn’t be a bad idea to retire as soon as I’m old enough.”
"But I understand you. You definitely want to make Sanqing bigger and stronger and become the national pride of China. Your career is more important to you than money. Otherwise, when you were about to go bankrupt, you would have sold Sanqing long ago. Cleared."
"Haha, Uncle Sun understands me. He is the one who watched me grow up."
Wei Kang smiled happily: "But don't worry, it's only 10 billion. It's just the difference between getting it now and getting it in two years."
"Furthermore, this price must have been leaked, and the cooperation conditions of other pharmaceutical companies will not be too different."
This is true. This price has persuaded most pharmaceutical companies to withdraw. After all, 10 billion euros is not something that ordinary pharmaceutical companies can afford.
Wei Kang continued: "I have decided that the main thing is to discuss cooperation with multinational giants. It is impossible to sell."
"But for cooperation, I prefer long-term cooperation, but they are definitely not willing to give up the initiative, so this is a difficult negotiation process. You have to shop around and try to choose a sincere partner."
"There are three options currently available. The first is equity investment cooperation, directly investing in the anti-cancer drug project and participating in subsequent development. However, this is generally more suitable in the early stages of new drug research and development. We have already produced results. If we let Giving out shares is equivalent to giving up, so this is excluded.”
"The second kind of agency cooperation is that we provide overseas agency rights for finished drugs. After they import them, they are responsible for subsequent development, even if they change their names and sell them under their own brands, and then we get the sales commission. This method has a high degree of freedom. , Logically speaking, it is the best way, but unfortunately Sanqing is too weak and does not have enough production capacity. It seems that we can only consider it in the future."
"The third option is authorized cooperation. We will soon be able to receive a large amount of advance payment, which will alleviate our urgent needs, and we will continue to receive income in the future. Although the total amount is limited, it can greatly promote the rapid growth of the company. This plan is currently the best Suitable for us.”
"However, this plan also has different conditions, and it still depends on the depth of cooperation between the two parties. If we can reach a strategic cooperation with a certain giant and jointly develop overseas markets, this plan would be the best."
"So we still have to have a good discussion with each giant and strive for the best conditions before we can finally make a decision."
Lao Sun said happily: "It seems that Mr. Wei, you have thought very clearly, and I very much agree with your idea."
Wei Kang put down the report in his hand and said: "Let's talk based on this standard. As for domestic pharmaceutical companies, I'll first look at their abandoned prescriptions. If there are good ones, don't give up. It's best to buy them. Since they have done them all I’ve prepared it as a gift, so I guess you won’t mind packaging it and selling it to us cheaper.”
"You! Why did you suddenly become so superstitious?" Lao Sun shook his head with a smile.
Wei Kang scratched his head and chuckled: "Isn't this a fluke caused by survivor bias? Who doesn't have a special preference?"
The two further discussed some details, and Lao Sun took his leave.
Wei Kang fell into deep thought.
The desk in front of him was neatly filled with cooperation plans from major pharmaceutical companies.
He reached out and picked up the plans of three international pharmaceutical companies, namely Pfizer, Bayer and Johnson & Johnson.
The plans of these three companies are currently the most convincing, but which one will be chosen in the end?
It still depends on the sincerity of the other party.
The choice is in his hands.
